Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Nominee Califf Seeks Clinical Trial, Combo Product Reforms

This article was originally published in The Gray Sheet

Executive Summary

President Obama nominated Robert Califf for FDA commissioner, and Senate HELP Chairman Lamar Alexander said the committee "will move promptly" to consider the nomination. If confirmed, he would be expected to lead reforms of the combination products review process, among other initiatives. However, while the initial positive response from Sen. Alexander suggests the possibility of a smooth confirmation, it certainly isn't guaranteed.

Advertisement

Related Content

Commissioner Califf: Cardiologist, Clinical Trials Expert Ascends At FDA
In Case You Missed It: Top 10 "Gray Sheet" Stories In September
Consumer Groups Oppose Califf To Head FDA, Citing Industry Ties
Combo Product Reforms Are A Priority For Next User Fee Round, FDA Officials Say
Podcast: FDA's Califf Talks About Combo Product Reform, Commish Prospects
Human Factors Questions Drive Rise In FDA Inter-Center Consults
FDA Commish Hamburg Gets Fond Farewell
Duke's Califf Tapped For FDA Deputy Post; Some See Succession Planning
IRB Reform Is Low-Hanging Fruit For FDA-Duke Clinical Trial Initiative
Larger Clinical Studies Required To Assess Device Risk/Benefit – Duke’s Califf

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT034208

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel